Telemedicus Appoints Medical Technology Advisory Board Member

Business Wire, Jan 2, 2008

HOUSTON -- Telemedicus, Inc. (OTC:TMDI), announced it has appointed David W. Mueller, CEO of Clear Vascular, Inc., to the Medical Technology Advisory Board.

"David brings a strong technical background in life sciences, especially in the areas of product development, technology transfer and venture capital, including pricing, leading and follow-up financing of venture backed companies," said Thomas Cloud, CEO Telemedicus, Inc. He added, "David Mueller has been an Interim CEO/COO/ Advisor in 16 startups over the past 23 years, and he served as director on 15 startups and one public company."

David Mueller was managing general partner/special limited partner of AM Fund, a partnership between a traditional venture fund and the Texas A&M University System. At Vanguard Ventures, he served as venture partner and as initial CEO/COO on six of Vanguard's portfolio companies.

Mr. Mueller has been General Manager of BCM Technologies, Inc., where he was responsible for day-to-day operations and strategic development for the technology transfer arm of Baylor College of Medicine. He was Manager of Technology Assessment and Director of Instrument Product Development at Medtronic, Inc. (NYSE: MDT). Finally, he has served high level management positions at Beckman Instruments, Tracor, Inc. and Texas A&M University Nuclear Science Center, and he was a member of the technical staff at Texas Instruments (NYSE: TXN).

Mr. Mueller graduated from Texas A&M University with a Bachelor of Science and earned a Ph.D. in Nuclear Chemistry.

The Advisory Board's objective is to evaluate new technology projects that fit within Telemedicus' development as well as identify new markets or opportunities for the Telemedicus technology. Their objectives also include attracting private funding or investments through venture capital fund managers.

"David Mueller will be of great assistance in identifying prospective takeover candidates and evaluating additional opportunities for Telemedicus," said Thomas Cloud, CEO Telemedicus Inc.

"The Telemedicus Technology" was developed by Texas A&M University and the University of Texas Health Science Department under a $20 million dollar Department of Defense grant. Telemedicus is the latest generation of mobile medical communication technology that allows a doctor to be "virtually onboard" the ambulance or medical-flight as the patient is transported to the hospital.

About Telemedicus, Inc:

Telemedicus, Inc. (OTC:TMDI) is a publicly held company headquartered in Houston, Texas. Telemedicus is commercializing life saving mobile medical communications technology using patented software and communications capabilities, proven solutions for bi-directional audio, video and patient data communication between a remote unit such as a rural ambulance service, med-flight helicopter, or a remote location such as My Healthy Access clinics, and the physician in a hospital trauma center. For more information please visit www.telemedicus.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.